Company Profile
Arcutis Biotherapeutics Stock Price, News & Analysis
- Ticker:
- ARQT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
26.43 USD (-2.47%)
Close
Last updated: August 6, 2026
2.6B USD
Market cap
Why the stock is moving
The latest monitored company update is “Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).” The corresponding closing-price reaction is not yet available.
Company overview
Medical Dermatology
Arcutis Biotherapeutics develops and commercializes targeted therapies for immune-mediated skin diseases, emphasizing convenient topical formulations against validated biology.
ZORYVE Franchise
ZORYVE is a once-daily topical roflumilast product available in cream and foam formulations across plaque psoriasis, atopic dermatitis and seborrheic dermatitis.
Pediatric Expansion
Arcutis is seeking to extend ZORYVE cream to infants with atopic dermatitis and ZORYVE foam to younger children with scalp and body plaque psoriasis.
New ZORYVE Indications
Phase 2 proof-of-concept studies are evaluating ZORYVE foam in vitiligo and hidradenitis suppurativa.
ARQ-234
ARQ-234 is a biologic candidate in initial clinical development for moderate-to-severe atopic dermatitis, expanding Arcutis beyond topical PDE4 inhibition.
Future catalysts
FDA review milestones for the ZORYVE cream infant-atopic-dermatitis sNDA.
Phase 2 vitiligo results and an advancement decision in the fourth quarter of 2026.
Phase 2 hidradenitis-suppurativa results and an advancement decision in the first quarter of 2027.
Recent news
- 01
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: Arcutis Biotherapeutics
- 02
Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
Source: Arcutis Biotherapeutics
- 03
Arcutis Expands Board of Directors with Appointment of Chris Peetz
Source: Arcutis Biotherapeutics
- 04
Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026
Source: Arcutis Biotherapeutics
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Arcutis Biotherapeutics (ARQT)?
Arcutis Biotherapeutics (ARQT) most recently closed at 26.43 USD, a -2.47% move versus the previous session.
What is the market cap of Arcutis Biotherapeutics (ARQT)?
Arcutis Biotherapeutics currently has a market capitalization of 2.6B USD on BioPharmSignal.
What does Arcutis Biotherapeutics do?
Medical Dermatology Arcutis Biotherapeutics develops and commercializes targeted therapies for immune-mediated skin diseases, emphasizing convenient topical formulations against validated biology. ZORYVE Franchise ZORYVE is a once-daily topical roflumilast product available in cream and foam formulations across plaque psoriasis, atopic dermatitis and...
On which exchange is ARQT stock listed?
Arcutis Biotherapeutics (ARQT) is associated with NASDAQ, United States, Biopharma.
What is ARQ-234?
ARQ-234 ARQ-234 is a biologic candidate in initial clinical development for moderate-to-severe atopic dermatitis, expanding Arcutis beyond topical PDE4 inhibition.
Which conditions is Arcutis Biotherapeutics targeting with ARQ-234?
Arcutis Biotherapeutics is associated with dermatology based on its company overview and current catalyst commentary.
How does Arcutis Biotherapeutics describe recent progress with ARQ-234?
FDA review milestones for the ZORYVE cream infant-atopic-dermatitis sNDA. Phase 2 vitiligo results and an advancement decision in the fourth quarter of 2026. Phase 2 hidradenitis-suppurativa results and an advancement decision in the first quarter of 2027.
What is proof-of-concept?
New ZORYVE Indications Phase 2 proof-of-concept studies are evaluating ZORYVE foam in vitiligo and hidradenitis suppurativa.